RXRX vs. DNA, SANA, APGE, CGON, BEAM, FUSN, INBX, KYMR, VCEL, and DNLI
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Ginkgo Bioworks (DNA), Sana Biotechnology (SANA), Apogee Therapeutics (APGE), CG Oncology (CGON), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), Inhibrx (INBX), Kymera Therapeutics (KYMR), Vericel (VCEL), and Denali Therapeutics (DNLI). These companies are all part of the "biological products, except diagnostic" industry.
Recursion Pharmaceuticals (NASDAQ:RXRX) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Recursion Pharmaceuticals has higher earnings, but lower revenue than Ginkgo Bioworks. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ginkgo Bioworks had 3 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 22 mentions for Ginkgo Bioworks and 19 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.45 beat Ginkgo Bioworks' score of 0.02 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.
Recursion Pharmaceuticals presently has a consensus price target of $12.75, indicating a potential upside of 48.26%. Ginkgo Bioworks has a consensus price target of $2.20, indicating a potential upside of 189.13%. Given Ginkgo Bioworks' higher probable upside, analysts plainly believe Ginkgo Bioworks is more favorable than Recursion Pharmaceuticals.
Ginkgo Bioworks has a net margin of -409.11% compared to Recursion Pharmaceuticals' net margin of -765.90%. Ginkgo Bioworks' return on equity of -52.85% beat Recursion Pharmaceuticals' return on equity.
Ginkgo Bioworks received 2 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. However, 51.22% of users gave Recursion Pharmaceuticals an outperform vote while only 50.00% of users gave Ginkgo Bioworks an outperform vote.
Recursion Pharmaceuticals has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.
89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 15.8% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 15.1% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Ginkgo Bioworks beats Recursion Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Recursion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Recursion Pharmaceuticals Competitors List
Related Companies and Tools
